Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies.

Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.83

Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008. Prostate (2015) 0.80

Serum markers in prostate cancer detection. Curr Opin Urol (2015) 0.80

Does obesity modify prostate cancer detection in a European cohort? Cent European J Urol (2017) 0.75

Editorial comment to Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. Int J Urol (2014) 0.75

Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ (2002) 9.29

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72

Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87

Missing... presumed at random: cost-analysis of incomplete data. Health Econ (2003) 2.38

Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res (2011) 1.71

Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57

Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev (2008) 1.44

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42

LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin Cancer Res (2009) 1.41

Identifying Ureters In Situ Under Fluorescence During Laparoscopic and Open Colorectal Surgery. Ann Surg (2016) 1.39

Placebo use in the United kingdom: results from a national survey of primary care practitioners. PLoS One (2013) 1.37

Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ (2006) 1.28

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart (2006) 1.26

Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. Int J Cancer (2005) 1.18

Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res (2011) 1.12

Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int (2008) 1.12

Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making (2009) 1.04

Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev (2009) 1.02

Current vaccination strategies for prostate cancer. Eur Urol (2011) 1.01

Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer (2011) 1.01

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00

Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol (2006) 1.00

PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression. Int J Cancer (2011) 0.98

Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int J Cancer (2009) 0.96

Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate (2010) 0.96

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2012) 0.94

Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update. Br J Gen Pract (2012) 0.92

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int (2008) 0.92

The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control (2010) 0.91

Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control (2012) 0.90

The D-Dimer test in combination with a decision rule for ruling out deep vein thrombosis in primary care: diagnostic technology update. Br J Gen Pract (2012) 0.90

Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One (2010) 0.90

Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Eff Resour Alloc (2010) 0.88

Bone morphogenetic protein- and mating-dependent secretory cell growth and migration in the Drosophila accessory gland. Proc Natl Acad Sci U S A (2012) 0.87

Point-of-care INR coagulometers for self-management of oral anticoagulation: primary care diagnostic technology update. Br J Gen Pract (2012) 0.83

Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. Eur J Cancer Prev (2013) 0.83

Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control (2011) 0.83

Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. J Health Serv Res Policy (2009) 0.82

Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials (2014) 0.81

Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. J Med Screen (2009) 0.81

The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Evidence from the MRC International Subarachnoid Aneurysm Trial. J Neurol (2009) 0.80

Point-of-care blood test for ketones in patients with diabetes: primary care diagnostic technology update. Br J Gen Pract (2011) 0.80

Dermoscopy for the diagnosis of melanoma: primary care diagnostic technology update. Br J Gen Pract (2011) 0.79

Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. Cancer Epidemiol (2010) 0.78

Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes Control (2012) 0.78

Economic evaluations in bipolar disorder: a systematic review and critical appraisal. Bipolar Disord (2014) 0.78

Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. Cancer Causes Control (2012) 0.77

Spirometry in primary care for case finding and management of chronic obstructive pulmonary disease primary care diagnostic technology update. Br J Gen Pract (2011) 0.77

Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. Int J Cancer (2014) 0.76

Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobin. Br J Gen Pract (2011) 0.75

Oral corticosteroid use for clinical and cost-effective symptom relief of sore throat: study protocol for a randomized controlled trial. Trials (2014) 0.75

The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. BMJ Open (2013) 0.75

Point-of-care testing for coeliac disease: primary care diagnostic technology update. Br J Gen Pract (2013) 0.75

From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap. Health Policy (2008) 0.75

Psychological distress and prostate specific antigen levels in men with and without prostate cancer. Brain Behav Immun (2009) 0.75